Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Single-chain Diabody) (SCDB-108)

Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Single-chain Diabody) is designed to be expressed as one polypeptide chain with four variable domains from two parental antibodies. The middle linker is long enough to form scFv dimers between the two diabody chains. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colon cancer; Rectal cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & VEGFR1

Type

Single-chain Diabody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colon cancer; Rectal cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

VEGFR1

Gene ID

2321

UniProt ID

P17948

Alternative Names

FLT1; fms-related tyrosine kinase 1; FLT; FLT-1; VEGFR1; VEGFR-1; vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Single-chain Diabody) (SCDB-108). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Single-chain Diabody) (CAT#: SCDB-108)

Specifications

Targets

Customer Reviews and Q&As